about
Improving clinical outcomes for naltrexone as a management of problem alcohol useTargeted opioid receptor antagonists in the treatment of alcohol use disordersAdvancing performance measures for use of medications in substance abuse treatmentPharmacotherapy for Alcohol Use Disorders: Physicians' Perceptions and PracticesCost-effectiveness of an internet-delivered treatment for substance abuse: Data from a multisite randomized controlled trial.Understanding attitudes towards use of medication in substance abuse treatment: A multilevel approach.Placebo group improvement in trials of pharmacotherapies for alcohol use disorders: a multivariate meta-analysis examining change over time.The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence.Facilitating factors and barriers to the use of medications in publicly funded addiction treatment organizationsNew pharmacotherapies for treating the neurobiology of alcohol and drug addiction.Organizational factors associated with the use of contingency management in publicly funded substance abuse treatment centersAdoption of injectable naltrexone in U.S. substance use disorder treatment programsOrganizational-level predictors of adoption across time: naltrexone in private substance-use disorders treatment centers.Views about responsibility for alcohol addiction and negative evaluations of naltrexone.Treatment of substance abusing patients with comorbid psychiatric disorders.Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.The role of expectation in the therapeutic outcomes of alcohol and drug addiction treatments.Access to Addiction Pharmacotherapy in Private Health Plans.Development of medications for alcohol use disorders: recent advances and ongoing challenges.Efficacy of disulfiram and Twelve Step Facilitation in cocaine-dependent individuals maintained on methadone: a randomized placebo-controlled trialA multi-level analysis of counselor attitudes toward the use of buprenorphine in substance abuse treatmentA perfect platform: combining contingency management with medications for drug abuseAdvancing recovery: implementing evidence-based treatment for substance use disorders at the systems levelLong-acting injectable naltrexone for the treatment of alcohol dependence.Acamprosate in the treatment of alcohol dependence: clinical and economic considerations.Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications DevelopmentWhat explains the diffusion of treatments for mental illness?Research on the diffusion of evidence-based treatments within substance abuse treatment: a systematic review.Effective Strategies for Maintaining Research Participation in Clinical Trials.The BRENDA model: integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders.The Role of Qualitative Research Methods in Discrete Choice ExperimentsDisparities in pharmacotherapy for alcohol use disorder in the context of universal health care: a Swedish register study.Barriers to and Facilitators of Alcohol Use Disorder Pharmacotherapy in Primary Care: A Qualitative Study in Five VA Clinics.
P2860
Q27021406-DAA4B02C-DBFA-4F8B-9594-62A9E511A6F8Q28295125-3E52D0F3-304C-42F8-9EF1-A2EC5E60B336Q28744415-2DBE32DC-DE9D-40A3-BD33-EFFA368D5BD8Q30275340-0604C1C2-CA0F-4160-B403-0284D4ACA5BCQ31046185-0B16F37D-E3DA-48D6-8E26-AC847DD0D73BQ33791771-2FD0DE41-AC1B-437A-AE8D-4200DDCA9EA8Q33828162-9E3A7622-EFD2-4DA0-9FCF-CD01D9472DFEQ34088940-646540ED-6752-4770-9B67-A7A8F3770067Q34111054-6049652C-645B-499C-9615-912C50126BB9Q34344220-A52152D1-BC86-4D62-AB8C-45D59507080AQ34384706-0BC6C04F-8841-4DFA-8FF8-7FCE5747FD39Q34682257-7A0E09E8-C0A2-4237-A0B8-D93A40C47969Q34711509-C348F31C-0A17-4B9D-A8C3-3A2E55A0D201Q35204253-CDB79986-8CC9-4E6C-9496-1755216CF5E8Q35387756-2C5E8D06-AB3C-4295-B6F5-94508B92A4A9Q35490468-1E86E6D7-22FC-4F03-A16C-21ACEBF55C46Q35555236-CDC4B480-DFDE-46EE-9576-C5A4BFDF71CAQ36025907-14FCEE44-CDF8-4ED8-8841-D2CBCCEDDE05Q36150622-F1F8E08E-7C64-41D8-8844-9A47C44E091CQ36287820-459BDAC4-65FE-4B23-9E7C-0819CECD656EQ36364490-3805795B-B71E-4838-BE88-A60BBF9FA730Q36631554-A60CCF68-1F5F-4A39-8CBC-CE47516AAD99Q36676519-945A4CFE-71CB-4897-B968-49947BF9D797Q36972683-B69837F8-5075-454B-B4A0-3310E802ADEBQ36998827-B0630171-2865-440B-8192-024C6D917236Q37059221-1C9EBCDF-0675-4DC9-9B14-15467EE28FFEQ37108584-92079358-CE17-4126-BFE9-3D93587C7B4EQ37224883-0380DC16-E87F-4FE1-B01F-BE7582BE2B3BQ37358442-0562BFF5-3225-449B-9DF5-4F42E57C9DE8Q37392393-C5280D84-519B-4204-B595-CC1EA1EDFFDFQ37722654-B9AC8C5F-9C3B-49DC-BA92-83530CBBDF38Q38838575-CFE86C0E-D76C-4796-B43C-B497CA4EE007Q47633289-5AD4B3D2-2123-4572-A47F-F9DA0F9B3E8A
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Barriers to the use of medications to treat alcoholism.
@ast
Barriers to the use of medications to treat alcoholism.
@en
type
label
Barriers to the use of medications to treat alcoholism.
@ast
Barriers to the use of medications to treat alcoholism.
@en
prefLabel
Barriers to the use of medications to treat alcoholism.
@ast
Barriers to the use of medications to treat alcoholism.
@en
P2093
P1476
Barriers to the use of medications to treat alcoholism.
@en
P2093
Carol A Hagen
Caroline McLeod
Henry R Kranzler
Scott Crosse
Tami L Mark
Virginia H Poole
P304
P356
10.1080/10550490390226879
P577
2003-07-01T00:00:00Z